Rockwell Medical, Inc. — Q3 2020 Form 10-Q
Business context and period. The unaudited filing covers the three and nine months ended September 30, 2020. Rockwell Medical manufactures dialysis concentrates and is developing iron therapies based on its ferric pyrophosphate citrate (FPC) platform. Dialysis concentrates generated approximately 96% of revenue in the first nine months. Triferic Dialysate was commercially launched in 2019; the FDA approved Triferic AVNU in March 2020.
Financial performance and position
- Q3 revenue: $15.280 million, down 0.8% from $15.407 million a year earlier. Gross profit was $0.346 million (2.3% margin), compared with a $0.017 million gross loss.
- Q3 operating and net loss: Operating loss was $6.690 million versus $7.942 million; net loss was $7.350 million versus $7.855 million. Basic and diluted loss per share was $0.10 versus $0.12.
- First nine months: Revenue was $47.033 million, up 2.7%; gross profit was $2.340 million (5.0% margin), up from $1.727 million (3.8%). Operating loss improved to $20.348 million from $27.123 million; net loss improved to $22.227 million from $26.826 million. Loss per share was $0.32 versus $0.45.
- Cash flow: Operating activities used $21.072 million in the first nine months, versus $21.954 million in 2019. Investing activities provided $2.575 million, principally reflecting net investment sales; financing activities provided $63.317 million.
- Liquidity: At September 30, cash and cash equivalents were $56.614 million and available-for-sale investments were $10.702 million, totaling $67.316 million. Working capital was $65.2 million; accumulated deficit was $328.743 million.
- Debt: The Innovatus term loan had $22.5 million principal outstanding and a $20.856 million carrying value, net of unamortized costs and discount. Initial interest was 8.75%; maturity is March 2025. The loan is secured by substantially all company and subsidiary assets.
- Equity and potential dilution: Shares outstanding rose from 65.4 million at year-end 2019 to 93.6 million at September 30, 2020. The September offering generated approximately $35.0 million gross proceeds and included warrants for up to 23.2 million shares, exercisable at $1.80 through September 2022.
Material changes versus prior periods
- Nine-month sales growth reflected higher domestic concentrate sales and approximately $0.4 million more Triferic Dialysate sales. Q3 revenue declined slightly, primarily due to lower international concentrate sales. Q3 Triferic drug revenue totaled $0.284 million; nine-month drug revenue was $0.776 million.
- Gross profit improved year over year, partly because the prior-year quarter included a larger inventory reserve. The company recorded $0.3 million of inventory reserves in Q3 2020 versus $1.1 million in Q3 2019; COVID-related labor and material costs partly offset the improvement.
- Nine-month selling and marketing expense fell 19.7% and general and administrative expense fell 28.0%, while research and product development expense increased 5.1%. Lower G&A included reduced stock compensation, legal, recruiting and consulting costs.
- Financing materially strengthened reported liquidity, through the term loan, public equity offerings and at-the-market share sales. Nine-month results also included $0.837 million of warrant modification expense and $1.289 million of interest expense.
Outlook, commentary and risks
- Management stated that available working capital and 2020 financing were expected to fund operations for at least 12 months from the filing date. It also said additional capital would be required for longer-term plans if product revenue is insufficient; future financing may not be available on favorable terms.
- Commercialization of Triferic remains a key dependency. Triferic AVNU clinic sampling began in Q3, but a packaging-production delay made commercial launch likely in Q1 2021. Both Triferic formulations are reimbursed within the existing dialysis payment bundle, which may slow adoption.
- The company warned that COVID-19 has disrupted sales and marketing, research and development, and partner activities, and could delay launches or clinical and regulatory work. It also creates uncertainty around access to future financing.
- Innovatus covenants include liquidity and Triferic sales tests. Rockwell was compliant at September 30, but management warned that annualized Triferic sales indicated it might not meet the sales covenant at December 31, 2020. A default could accelerate repayment and adversely affect liquidity.
- Triferic inventory totaled $3.8 million before a $2.7 million reserve, leaving $1.1 million net value. The filing identifies shelf-life and adoption risks, including near-dated finished goods.
- Disclosure controls and procedures were deemed ineffective at September 30 because material weaknesses’ pervasive effects on other IT-dependent control cycles remained under evaluation. Management said the financial statements were fairly stated and described ongoing remediation efforts.
- Legal matters include an ongoing SEC investigation. A securities class action settlement was court-approved, and the derivative action settlement was funded by D&O insurance. A supplier dispute was settled, with raw-material payment obligations under the amended agreement.
Important facts for investors to verify
- Progress and sales adoption for Triferic Dialysate and the revised Triferic AVNU launch timing, including any effect on revenue and inventory write-offs.
- Whether the company meets Innovatus liquidity and Triferic sales covenants, especially the test beginning with the period ending December 31, 2020, and whether any cure or waiver is needed.
- Operating cash burn relative to available liquidity and management’s stated 12-month funding outlook; assess the need and terms of any further financing.
- Potential dilution from outstanding warrants and other equity awards, alongside the increase in common shares outstanding.
- Progress remediating the remaining internal-control weakness and any updates to the SEC investigation or other legal matters.